Siemens Healthineers Get FDA Nod for MAGNETOM Free.Star MRI Scanner
The new magnetic resonance imaging (MRI) device reportedly offers deep learning technologies and advanced processing of whole-body images in a cost-effective and lightweight model.
An emerging whole body magnetic resonance imaging (MRI) system may provide enhanced imaging capabilities with lower costs and energy consumption in comparison to conventional whole body MRI scanners.
The MAGNETOM Free.Star MRI scanner, recently cleared by the Food and Drug Administration (FDA), offers targeted denoising and high-resolution scans through artificial intelligence (AI)-powered Deep Resolve algorithms, according to Siemens Healthineers, the manufacturer of the MRI system.
Noting that the MAGNETOM Free.Star device is the smallest and most lightweight whole-body MRI system it has manufactured, the company emphasized that it requires less than one liter of liquid helium and no quench pipe. Siemens Healthineers said the reduced energy consumption can lead to a greater than 30 percent reduction in lifecycle costs of the device in comparison to other MRI devices.
Siemens Healthineers noted another aspect of the modality is the myExam Companion, which enhances exam efficiency through AI.
“The MAGNETOM Free.Star is further proof of our steadfast commitment to providing customers with MRI scanners that are more cost-effective, more easily operable, and more easily sited for installation at a wide variety of healthcare institutions across the United States,” noted Jane Kilkenny, the vice president of MR Business Management at Siemens Healthineers.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
